Hetronifly (serplulimab) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento Infarmed

Hetronifly (serplulimab) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento
swki.me/l5ZKFgUk
#infarmed #medicamentos #financiamentopublico #hetronifly #serplulimab

Henlius Achieves Strong Revenue Growth and Innovation Validation in 2025 Results Report Henlius has announced its impressive 2025 annual results, highlighting three consecutive years of profitability, significant revenue growth, and innovation advancements.

Henlius Achieves Strong Revenue Growth and Innovation Validation in 2025 Results Report #China #Shanghai #biotechnology #Henlius #Serplulimab

Henlius Reports Sustained Growth in Revenues and Profits for 2025 In 2025, Henlius announced impressive financial results, marking its third consecutive year of profitability, growing income and profits significantly.

Henlius Reports Sustained Growth in Revenues and Profits for 2025 #China #Shanghai #Henlius #Hanquyou #Serplulimab

Henlius Reports Strong Growth and Market Expansion in 2025 Financial Results Henlius showcases remarkable financial growth in 2025, marking the third consecutive profitable year, with significant success in global market penetration and innovation.

Henlius Reports Strong Growth and Market Expansion in 2025 Financial Results #China #Shanghai #Henlius #Hanquyou #Serplulimab

Henlius Achieves Record Growth in 2025 with Strong Profitability and Product Innovation Henlius has reported impressive 2025 results with significant revenue growth and sustained profitability, highlighting its innovation in the global biopharma market.

Henlius Achieves Record Growth in 2025 with Strong Profitability and Product Innovation #China #Shanghai #biotech #Henlius #Serplulimab

Henlius 2025 Annual Results Showcase Unprecedented Revenue and Profit Growth Amidst Global Expansion Efforts Henlius shares impressive 2025 annual results showing significant revenue growth, profit increase, and advancements in global biopharmaceutical operations.

Henlius 2025 Annual Results Showcase Unprecedented Revenue and Profit Growth Amidst Global Expansion Efforts #China #Shanghai #Serplulimab #Henlius_Biotech #HERCESSI

Eisai and Henlius Secure Exclusive Agreement for Serplulimab in Japan Eisai and Henlius have announced a groundbreaking exclusive licensing deal for the anti-PD-1 antibody Serplulimab in Japan. This agreement is set to enhance cancer treatment options in the region.

Eisai and Henlius Secure Exclusive Agreement for Serplulimab in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Eisai and Henlius Strike Exclusive Deal for Serplulimab in Japan Eisai Co. and Henlius Biotech have reached a significant licensing agreement to commercialize the novel anti-PD-1 antibody serplulimab in Japan, enhancing cancer treatment options.

Eisai and Henlius Strike Exclusive Deal for Serplulimab in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Eisai and Henlius Join Forces for Innovative Cancer Treatment in Japan Eisai and Henlius have announced a commercial agreement for the anti-PD-1 antibody serplulimab, enhancing cancer treatment options in Japan.

Eisai and Henlius Join Forces for Innovative Cancer Treatment in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Eisai and Henlius Forge Licensing Deal for Serplulimab in Japan Eisai and Henlius have signed an exclusive agreement for the commercialization of the anti-PD-1 drug Serplulimab in Japan, enhancing cancer treatment options.

Eisai and Henlius Forge Licensing Deal for Serplulimab in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Eisai and Henlius Collaborate to Bring Serplulimab to Japanese Patients Eisai and Henlius announce a partnership to exclusively commercialize Serplulimab in Japan, a groundbreaking anti-PD-1 antibody targeting unmet medical needs.

Eisai and Henlius Collaborate to Bring Serplulimab to Japanese Patients #Japan #Tokyo #Eisai #Henlius #Serplulimab

Accord Healthcare Secures MHRA Approval for Innovative Lung Cancer Treatment Hetronifly® Accord Healthcare has obtained MHRA approval for Hetronifly®, a groundbreaking treatment for advanced small cell lung cancer, enhancing treatment options for patients.

Accord Healthcare Secures MHRA Approval for Innovative Lung Cancer Treatment Hetronifly® #London #United_Kingdom #Accord_Healthcare #Serplulimab #Hetronifly

Accord Healthcare Announces Approval of Hetronifly® for Lung Cancer Treatment Accord Healthcare's Hetronifly® (Serplulimab) gets the green light from MHRA for treating extensive-stage small cell lung cancer, marking a significant advance in cancer care.

Accord Healthcare Announces Approval of Hetronifly® for Lung Cancer Treatment #London #United_Kingdom #Accord_Healthcare #Serplulimab #Hetronifly

Accord Healthcare Secures MHRA Approval for Hetronifly® in Small Cell Lung Cancer Therapy Accord Healthcare has received pivotal MHRA approval for Hetronifly® (Serplulimab) as a groundbreaking treatment for extensive-stage small cell lung cancer, marking a significant advancement in cancer care.

Accord Healthcare Secures MHRA Approval for Hetronifly® in Small Cell Lung Cancer Therapy #London #United_Kingdom #Accord_Healthcare #Serplulimab #Hetronifly

Accord Healthcare's Serplulimab Gains MHRA Approval for Lung Cancer Therapy in the UK Accord Healthcare's Hetronifly®, a new lung cancer treatment, has received MHRA approval for use in extensive-stage small cell lung cancer, expanding treatment options for patients.

Accord Healthcare's Serplulimab Gains MHRA Approval for Lung Cancer Therapy in the UK #London #United_Kingdom #Accord_Healthcare #Serplulimab #Hetronifly

The ASTRUM-004 Phase 3 trial delivered promising results for advanced squamous #NSCLC! Adding serplulimab to 1L CT significantly improved survival vs. CT alone.

@cp-cancercell.bsky.social

#Onco404 #Cancer #Kanser #MedSky #OncSky #AkciğerKanseri #Immunotherapy #İmmünoterapi #Serplulimab #ASTRUM004

Henlius R&D Day 2025: Collaboration Drives Global Innovation Strategy Forward Henlius held its 2025 Global R&D Day under the theme 'Collaborate to Create,' showcasing innovative therapies and strategic growth.

Henlius R&D Day 2025: Collaboration Drives Global Innovation Strategy Forward #China #Shanghai #Henlius #Serplulimab #HLX22

Accord Healthcare's Hetronifly® Gains EU Approval for Extensive-Stage Lung Cancer Treatment Accord Healthcare's Hetronifly® has received EU market authorization for treating extensive-stage small cell lung cancer, marking a significant advancement in oncology.

Accord Healthcare's Hetronifly® Gains EU Approval for Extensive-Stage Lung Cancer Treatment #None #Accord_Healthcare #Serplulimab #Hetronifly®

Accord Healthcare's Hetronifly® Receives European Approval for Lung Cancer Treatment Accord Healthcare has unveiled that Hetronifly® (serplulimab) has secured approval from the European Commission for treating extensive-stage small cell lung cancer (ES-SCLC).

Accord Healthcare's Hetronifly® Receives European Approval for Lung Cancer Treatment #None #Accord_Healthcare #Serplulimab #Hetronifly

Accord Healthcare's Hetronifly® Gains European Approval for Advanced Lung Cancer Treatment Accord Healthcare's serplulimab, known as Hetronifly®, has received CE approval for treating advanced lung cancer, ensuring new patient options.

Accord Healthcare's Hetronifly® Gains European Approval for Advanced Lung Cancer Treatment #London #United_Kingdom #Accord_Healthcare #Serplulimab #Hetronifly

Serplulimab Gains European Approval as First-Line Treatment for ES-SCLC Serplulimab has achieved a monumental milestone, becoming the first anti-PD-1 monoclonal antibody approved in the EU for extensive-stage small cell lung cancer treatment.

Serplulimab Gains European Approval as First-Line Treatment for ES-SCLC #China #Shanghai #Henlius #Serplulimab #HANSIZHUANG